11
Sino Biopharma
1177.HK·HKEXHong Kong CNFounded 200030,000 employees
Large CappharmaPublicOncologyHematology
Platform: CT Frontier
Market Cap
$12B
All Drugs
5
Clinical Trials
11
Failed / Terminated
0
FDA Approved
1
Stock Price & Catalysts (1177.HK)
Loading 1177.HK stock data...
Drug Pipeline (5 programs)
| Drug Name | Code | Phase | Trials | Modality | Target | MOA | Indications |
|---|---|---|---|---|---|---|---|
| Nirasacituzumab | 117-8907 | Phase 3 | 4 | EGFR | SMAMelanoma | ||
| 117-5200 | 117-5200 | Phase 2 | 1 | RET | SMA | ||
| 117-9336 | 117-9336 | Phase 2/3 | 1 | PLK4 | Endometrial CaGastric Ca | ||
| Lisosertib | 117-1671 | Phase 1 | 2 | CD3 | MSMeso | ||
| Lisolemzoparlimab | 117-7182 | Approved | 3 | AuroraA | EoEHNSCC |
SEC Filings & Financial Documents
SEC filings are not available for HKEX-listed companies.
Sino Biopharma trades on HKEX (CN). SEC EDGAR only covers US-listed issuers.
Insider Trading Activity
Insider trading data is not available for non-US exchanges.
Catalyst Events (9)